March 31, 2020 10:32 AM EDTUpdated 02:41 PM

Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays

ENDPOINTS

→ Having just filed for the European approval of its uterine fibroids drug relugolix, Myovant has sold the regional rights off to Hungarian biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

My­ovant grabs $40M up­front in re­gion­al deal for re­l­u­golix; Akero an­nounces NASH suc­cess but Covid-19 de­lays

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays